Coexistent Sickle Cell Disease has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke
Stroke 48:686-691, Adams, R.J.,et al, 2017
Monitoring long-term Efficacy of Fampridine in Gait-Impaired Patients with Multiple Sclerosis
Neurol 88:832-841, Filli, L.,et al, 2017
Investigations in GABA? Receptor Antibody-Associated Encephalitis
Neurol 88:1012-1020,1010, Spatola, M.,et al, 2017
Clinicopathologic Conference Cryptococcal Meningitis in a Patient with Chronic HIV Infection
NEJM 376:1065-1071, Case 8-2017, 2017
Short-Course Radiation Plus Temozolomide in Elderly Patients with Glioblastoma
NEJM 376:1027-1037, Perry, J.R.,et al, 2017
Management of Sciatica
NEJM 376:1175-1177, Ramaswami, Ramya, 2017
Trial of Pregabalin for Acute and Chronic Sciatica
NEJM 376:1111-1120, Mathieson, S.,et al, 2017
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Association of Spinal Manipulative Therapy with Clinical Benefit and Harm for Acute Low Back Pain
JAMA 317:1451-1460,1418, Paige, N.M.,et al, 2017
Long-Term Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
JAMA Neurol 74:459-469,392, Muraro, P.A.,et al, 2017
Morvan Syndrome as a Paraneoplastic Disorder of Thymoma with Anti-CASPR2 antibodies
Lancet 389:1367-1368, Vale, T.C.,et al, 2017
Acute Spinal Cord Compression
NEJM 376:1358-1369, Ropper, A.E. & Ropper, A.H., 2017
Two-Year Outcome after Endovascular Treatment for Acute Ischemic Stroke
NEJM 376:1341-1349, Van Den Berg, L.A.,et al, 2017
Reversible Gait Ataxia
Neurol 88:e145-e149, Abkur, T.M. & Bede, P., 2017
Intracranial Dural Arteriovenous Fistulae
Stroke 48:1424-1431, Reynolds, M.R.,et al, 2017
Patient with Severe Moyamoya Disease Who Presents with Acute Cortical Blindness
Stroke 48:e126-e129, Sajja, A.,et al, 2017
A Child with Delayed Motor Milestones and Ptosis
Neurol 88:e158-e163, Ghosh, P.S., 2017
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
NEJM 376:1627-1636, Calkins, H.,et al, 2017
Subarachnoid Hemorrhage
NEJM 377:257-266, Lawton, M.T. & Vates, G.E., 2017
Lumbar Puncture Test in Normal Pressure Hydrocephalus: Does the Volume of CSF Removed Affect the Response to Tap?
AJNR 38:1456-1460, Thakur, S.K., et al, 2017
TIPIC Syndrome: Beyond the Myth of Carotidynia, a New Distinct Unclassified Entity
AJNR 38:1391-1398, Lecler, A.,et al, 2017
Amyotrophic Lateral Sclerosis
NEJM 377:162-172, Brown, R.H.,et al, 2017
Trial of Tocilizumab in Giant-Cell Arteritis
NEJM 377:317-328,385, Stone, J.H.,et al, 2017
A Demure Teenager and Her Dystonic Foot
Neurol 89:e71-e75, Cullinane, P.W.,et al, 2017
Quality Improvement in Neurology: Inpatient and Emergency Care Quality Measure Set
Neurol 89:730-735, Josephson, S.An.,et al, 2017
Effect of Gluten-Free Diet on Cerebellar MR Spectroscopy in Gluten Ataxia
Neurol 89:705-709, Hadjivassiliou, M.,et al, 2017
Migraine
NEJM 377:553-561, Charles, A., 2017
Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern?
NEJM 377:411-414, Goodman, C.W. & Brett, A.S., 2017
CT Angiography ASPECTS Predicts Outcome Much Better Than Noncontrast CT in Patients with Stroke Treated Endovascularly
AJNR 38:1569-1573, Sallustio, F.,et al, 2017
Dentate Update: Imaging Features of Entities that Affect the Dentate Nucleus
AJNR 38:1467-1474, Bond, K.M.,et al, 2017
Overview of IgG4-related Disease
UptoDate, July, Moutsopoulos,H.,et al, 2017
A 50-year-old Woman with SLE and a Tumefactive Lesion
Neurol 89:e140-e145, Choi, J.H.,et al, 2017
Thalamic Deep Brain Stimulation for Tremor in Parkinson Disease, Essential Tremor, and Dystonia
Neurol 89:1416-1423, Cury, R.G.,et al, 2017
Diagnostic Challenges in a Young Patient with Hypereosinophilia
Neurol 89:e159-e165, Ortiz, J.G.,et al, 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
National Randomized Controlled Trial of Virtual House Calls for Parkinson Disease
Neurol 89:1152-1161,1103, Beck, C.A.,et al, 2017
Zolpidem for the Treatment of Neurologic Disorders
JAMA Neurol 74:1130-1139, Bomalaski, M.N.,et al, 2017
Management of Parkinson Disease in 2017
JAMA 318:791-792, Okun, M.S.,et al, 2017
A 27-year-old man with unsteady gait
Neurol 89:e120-e123, Fernandez, D.,et al, 2017
Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
Chess Study Revives Debate Over Cognition-Enhancing Drugs
JAMA doi:10.1001/JAMA:2017.8114, Lyon, J., 2017
DAWN: Thrombectomy Effective Up to 24 Hours after Stroke
Medscape May, Hughes, S., 2017
Computed Tomographic Perfusion to Predict Response to Recanalization in Ischemic Stroke
Ann Neurol 81:849-856, Lansberg, M.G.,et al, 2017
Clinicopathologic Conference, Diffuse Large B-Cell Lymphoma Consistent with Neurolymphomatosis
NEJM 376:2471-2481, Case 19-2017, 2017
Endovascular Therapies for Acute Ischemic Stroke in Children
Stroke 48:2026-2030, Huang, M.I.,et al, 2017
Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia
NEJM 376:2503-2506, Davis, M.C.,et al, 2017